Although merger and acquisition activity in the South Korean biopharma sector is viewed as relatively timid compared to the global market, it seems to have increased notably since the end of the COVID-19 pandemic, with more keen interest in the field from domestic non-biopharma conglomerates as well as financial investors.
While deals in closely watched "hot" sectors such as antibody-drug conjugates (ADCs) may be similar to those happening in the rest of the world, there seem to be certain significant differences between M&A trends at home and abroad, with some of the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?